Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 12/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.41 |
| ▸ | GNG2 | P59768 | 1/20 | 0.36 |
| ▸ | GNB1 | P62873 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21551956 | 0.88 | MAPT (0.39) | GSK3BUSP2F2L3MBTL1ALDH1A1 | |
| SCHEMBL18129375 | 0.86 | GSK3B (0.53) | GSK3BPTPN1ALDH1A1HPGDSRD5A1 | |
| SCHEMBL15083844 | 0.86 | GSK3B (0.53) | GSK3BPTPN1ALDH1A1HPGDSRD5A1 | |
| SCHEMBL21551963 | 0.85 | HSD17B3 (0.42) | USP2F2L3MBTL1ALDH1A1HPGD | |
| SCHEMBL5215126 | 0.85 | PTPN1 (0.49) | GSK3BPTPN1PDK2 | |
| SCHEMBL21551942 | 0.83 | HSD17B3 (0.45) | ALDH1A1 | |
| SCHEMBL21333830 | 0.83 | SRD5A2 (0.53) | HPGDSRD5A1SRD5A2PDK2 | |
| SCHEMBL4998169 | 0.83 | MAPT (0.47) | ALDH1A1HPGDSRD5A1SRD5A2PDK2 | |
| SCHEMBL16868667 | 0.80 | GSK3B (0.46) | GSK3BPTPN1USP2F2L3MBTL1 | |
| SCHEMBL16868638 | 0.80 | GSK3B (0.46) | GSK3BPTPN1USP2F2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
| WO-2013021344-A1 | IMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | LUPIN LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
| WO-2013021344-A1 | IMIDAZOLE DERIVATIVES AS ANTIVIRAL AGENTS | LUPIN LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | GSK3B 591/4885PTPN1 417/4885GNG2 3377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.